![]() Eyes in the CTGVA group with as-needed treatment received fewer mean (SD) injections in year 1 (5.8 vs 8.1 ) and year 2 (7.7 vs 13.8 ) than eyes in the other as-needed group. Baseline characteristics were similar between eyes in the CTGVA and other groups, except for better visual acuity letter score in the study eye (68.8 vs 61.8 P = .001) and the fellow eye (78.4 vs 68.0 P = .01) as well as the presence of blocked fluorescence seen more often in participants in the CTGVA vs the other group (27.5% vs 13.8% P = .02). These 40 participants, compared with the other group (n = 585), had a lower mean (SD) age of 74.7 (7.3) years (vs 77.7 years P = .01) and included 26 women (65.0%). Results Among 625 eyes with nAMD at baseline and a visual acuity measurement at year 5, 40 (6.4% 95% CI, 4.7%-8.7%) were included in the analysis. Main Outcomes and Measures Visual acuity, morphologic characteristics, and number of treatments over 5 years. This present analysis, conducted from December 1, 2018, to September 30, 2019, compared the eyes of 40 participants (referred to as the cessation of treatment with good visual acuity, or CTGVA, group) with the eyes of the remainder of the CATT Follow-up Study (referred to as the other group). At year 5, participants were recalled for examination. At year 2, participants were released from the protocol to treatment at the discretion of their ophthalmologist. After initial randomization to 1 of 4 treatment groups (ranibizumab monthly, bevacizumab monthly, ranibizumab as needed, or bevacizumab as needed), at year 1, participants in the monthly groups were rerandomized to continue monthly treatment or to switch to as-needed treatment using the same drug as originally assigned. Objectives To ascertain the characteristics of eyes in the CATT that retained good vision despite receiving no therapy for 3 years after release from the 2-year CATT treatment protocol.ĭesign, Setting and Participants This case-control study analyzed the baseline and follow-up characteristics of eyes with nAMD that were enrolled in the CATT from 43 US clinical centers between February 20, 2008, and December 9, 2009. Importance Identifying the characteristics of eyes with neovascular age-related macular degeneration (nAMD) that maintain good vision without anti–vascular endothelial growth factor treatment for at least 3 years after management, as occurred in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), may have prognostic importance and help in understanding the disease and its treatment. Shared Decision Making and Communication.Scientific Discovery and the Future of Medicine. ![]() Health Care Economics, Insurance, Payment.Clinical Implications of Basic Neuroscience.Challenges in Clinical Electrocardiography. ![]() A "Maintenance of Certification Program" encourages board certified physicians to continue learning and self-evaluating throughout their medical career. MOC - She does not participate in the Medicare Maintenance of Certification Program.Million Hearts is a national initiative that encourages health care professionals to report and perform well on activities related to heart health in an effort to prevent heart attacks and strokes. MHI - She does not commit to heart health through the Million Hearts initiative.Electronic health records are important because they may improve a health care professional's ability to make well-informed treatment decisions. The Electronic Health Records (EHR) Incentive Program encourages health care professionals to use certified EHR technology in ways that may improve health care. EHR - She does use electronic health records (EHR).Quality measures can show how well a health care professional provides care to people with Medicare. The Physician Quality Reporting System (PQRS) is a Medicare program encouraging health care professionals and group practices to report information on their quality of care. PQRS - She does report Quality Measures (PQRS).eRx - She does not participate in the Medicare Electronic Prescribing (eRx) Incentive Program.NPPES Last Update: Wednesday, February 6, 2013. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |